DYN
Dyne Therapeutics, Inc.$18.05-0.47 (-2.54%)Prev Close$18.52·MCap$4.53B·P/E—·Vol2.26M·Yield—
▲
Buys (12M)
7
$274.8K
▼
Sells (12M)
38
$168.62M
◆
Net Activity
Net Seller
$168.34M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Dyne Therapeutics, Inc. (DYN) has been dominated by selling, with 7 insider purchases totaling $274.8K and 38 insider sales totaling $168.62M. The most recent insider transaction was by Cox John (director, officer: CEO & President), who sold $106.8K worth of shares on Sep 8, 2026. Dyne Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $4.53B.
DYN Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Cox John | director, officer: CEO & President | Sell | 5,658 | $18.88 | $106.8K | 357,507 |
| Sep 8, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 1,085 | $23.42 | $25.4K | 153,082 |
| Sep 8, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 5,035 | $22.95 | $115.5K | 163,854 |
| Aug 17, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 226 | $26.28 | $5.9K | 153,982 |
| Aug 17, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 1,797 | $26.28 | $47.2K | 119,766 |
| Aug 17, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 1,556 | $26.28 | $40.9K | 167,599 |
| Aug 17, 2026 | Rhodes Jason P | director | Sell | 2,586,928 | $25.20 | $65.18M1.4% OS | 3,801,128-40% |
| Aug 17, 2026 | Cox John | director, officer: CEO & President | Sell | 4,986 | $26.28 | $131.0K | 363,165 |
| Jul 29, 2026 | Kersten Dirk | director | Sell | 261,460 | $25.51 | $6.67M | 3,592,184 |
| Jul 8, 2026 | Rhodes Jason P | director | Sell | 777,451 | $22.97 | $17.86M | 4,223,448 |
| Jun 30, 2026 | Rhodes Jason P | director | Sell | 504,695 | $21.23 | $10.71M | 4,579,456 |
| Jun 26, 2026 | Rhodes Jason P | director | Sell | 267,760 | $21.09 | $5.65M | 4,805,639 |
| Jun 26, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 2,362 | $20.37 | $48.1K | 121,563 |
| Jun 24, 2026 | Kersten Dirk | director | Sell | 263,962 | $20.70 | $5.46M | 3,921,542 |
| Jun 22, 2026 | Kersten Dirk | director | Sell | 84,355 | $20.10 | $1.70M | 4,159,119 |
| Jun 17, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 145 | $18.33 | $2.7K | 154,208 |
| Jun 17, 2026 | Cox John | director, officer: CEO & President | Sell | 2,683 | $18.33 | $49.2K | 368,151 |
| Jun 17, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 887 | $18.33 | $16.3K | 169,155 |
| Jun 9, 2026 | Posner Brian S | director | Buy | 2,000 | $16.94 | $33.9K | 24,500 |
| Jun 5, 2026 | Posner Brian S | director | Buy | 2,500 | $17.48 | $43.7K | 22,500 |
| May 28, 2026 | Posner Brian S | director | Buy | 2,000 | $18.21 | $36.4K | 20,000 |
| May 22, 2026 | Posner Brian S | director | Buy | 2,500 | $17.12 | $42.8K | 18,000 |
| May 14, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 1,564 | $18.36 | $28.7K | 170,042 |
| May 14, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 228 | $18.36 | $4.2K | 154,353 |
| May 14, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 1,448 | $18.36 | $26.6K | 123,925 |
| May 14, 2026 | Cox John | director, officer: CEO & President | Sell | 3,311 | $18.36 | $60.8K | 370,834 |
| May 6, 2026 | Rhodes Jason P | director | Sell | 106,723 | $18.14 | $1.94M | 4,933,196 |
| Apr 30, 2026 | Rhodes Jason P | director | Sell | 227,337 | $18.38 | $4.18M | 4,939,489 |
| Apr 27, 2026 | Rhodes Jason P | director | Sell | 384,549 | $18.47 | $7.10M | 5,221,857 |
| Apr 23, 2026 | Kersten Dirk | director | Sell | 10,952 | $20.01 | $219.2K | 4,199,225 |
| Apr 22, 2026 | Rhodes Jason P | director | Sell | 834,302 | $19.75 | $16.48M0.5% OS | 5,554,904 |
| Apr 21, 2026 | Kersten Dirk | director | Sell | 337,248 | $20.21 | $6.82M | 4,332,799 |
| Apr 17, 2026 | Kersten Dirk | director | Sell | 99,613 | $20.35 | $2.03M | 4,562,546 |
| Apr 3, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 5,727 | $18.64 | $106.8K | 125,373 |
| Apr 1, 2026 | Posner Brian S | director | Buy | 2,000 | $17.08 | $34.2K | 15,500 |
| Mar 13, 2026 | Kersten Dirk | director | Sell | 129,672 | $19.52 | $2.53M | 4,644,386 |
| Mar 13, 2026 | Posner Brian S | director | Buy | 2,000 | $19.35 | $38.7K | 13,500 |
| Mar 11, 2026 | Kersten Dirk | director | Sell | 688,788 | $19.09 | $13.15M | 5,285,156 |
| Mar 10, 2026 | Posner Brian S | director | Buy | 3,000 | $15.06 | $45.2K | 11,500+35% |
| Mar 6, 2026 | Cox John | director, officer: CEO & President | Sell | 2,732 | $14.90 | $40.7K | 374,145 |
| Mar 6, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 148 | $14.90 | $2.2K | 154,581 |
| Mar 6, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 904 | $14.90 | $13.5K | 171,606 |
| Dec 5, 2025 | Cox John | CEO & President | Sell | 2,662 | $20.72 | $55.2K | 196,877 |
| Dec 5, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 144 | $20.72 | $3.0K | 94,729 |
| Dec 5, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 880 | $20.72 | $18.2K | 87,510 |
| Sep 9, 2025 | Cox John | CEO & President | Sell | 2,640 | $13.41 | $35.4K | 199,539 |
| Sep 8, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 1,038 | $13.29 | $13.8K | 95,017 |
| Sep 8, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 4,425 | $13.30 | $58.8K | 89,263 |
| Jul 15, 2025 | Cox John | CEO & President | Buy | 100,000 | $9.11 | $911.0K | 242,179+70% |
| Jun 6, 2025 | Cox John | CEO & President | Sell | 4,060 | $13.35 | $54.2K | 142,179 |
Showing 1–50 of 199
1 / 4
DYN Insider Buying Activity
The following table shows recent insider purchases of Dyne Therapeutics, Inc. (DYN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Posner Brian S | director | Buy | 2,000 | $16.94 | $33.9K | 24,500 |
| Jun 5, 2026 | Posner Brian S | director | Buy | 2,500 | $17.48 | $43.7K | 22,500 |
| May 28, 2026 | Posner Brian S | director | Buy | 2,000 | $18.21 | $36.4K | 20,000 |
| May 22, 2026 | Posner Brian S | director | Buy | 2,500 | $17.12 | $42.8K | 18,000 |
| Apr 1, 2026 | Posner Brian S | director | Buy | 2,000 | $17.08 | $34.2K | 15,500 |
| Mar 13, 2026 | Posner Brian S | director | Buy | 2,000 | $19.35 | $38.7K | 13,500 |
| Mar 10, 2026 | Posner Brian S | director | Buy | 3,000 | $15.06 | $45.2K | 11,500+35% |
| Jul 15, 2025 | Cox John | CEO & President | Buy | 100,000 | $9.11 | $911.0K | 242,179+70% |
DYN Insider Selling Activity
The following table shows recent insider sales of Dyne Therapeutics, Inc. (DYN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Cox John | director, officer: CEO & President | Sell | 5,658 | $18.88 | $106.8K | 357,507 |
| Sep 8, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 1,085 | $23.42 | $25.4K | 153,082 |
| Sep 8, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 5,035 | $22.95 | $115.5K | 163,854 |
| Aug 17, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 226 | $26.28 | $5.9K | 153,982 |
| Aug 17, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 1,797 | $26.28 | $47.2K | 119,766 |
| Aug 17, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 1,556 | $26.28 | $40.9K | 167,599 |
| Aug 17, 2026 | Rhodes Jason P | director | Sell | 2,586,928 | $25.20 | $65.18M1.4% OS | 3,801,128-40% |
| Aug 17, 2026 | Cox John | director, officer: CEO & President | Sell | 4,986 | $26.28 | $131.0K | 363,165 |
| Jul 29, 2026 | Kersten Dirk | director | Sell | 261,460 | $25.51 | $6.67M | 3,592,184 |
| Jul 8, 2026 | Rhodes Jason P | director | Sell | 777,451 | $22.97 | $17.86M | 4,223,448 |
| Jun 30, 2026 | Rhodes Jason P | director | Sell | 504,695 | $21.23 | $10.71M | 4,579,456 |
| Jun 26, 2026 | Rhodes Jason P | director | Sell | 267,760 | $21.09 | $5.65M | 4,805,639 |
| Jun 26, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 2,362 | $20.37 | $48.1K | 121,563 |
| Jun 24, 2026 | Kersten Dirk | director | Sell | 263,962 | $20.70 | $5.46M | 3,921,542 |
| Jun 22, 2026 | Kersten Dirk | director | Sell | 84,355 | $20.10 | $1.70M | 4,159,119 |
| Jun 17, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 145 | $18.33 | $2.7K | 154,208 |
| Jun 17, 2026 | Cox John | director, officer: CEO & President | Sell | 2,683 | $18.33 | $49.2K | 368,151 |
| Jun 17, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 887 | $18.33 | $16.3K | 169,155 |
| May 14, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 1,564 | $18.36 | $28.7K | 170,042 |
| May 14, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 228 | $18.36 | $4.2K | 154,353 |
| May 14, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 1,448 | $18.36 | $26.6K | 123,925 |
| May 14, 2026 | Cox John | director, officer: CEO & President | Sell | 3,311 | $18.36 | $60.8K | 370,834 |
| May 6, 2026 | Rhodes Jason P | director | Sell | 106,723 | $18.14 | $1.94M | 4,933,196 |
| Apr 30, 2026 | Rhodes Jason P | director | Sell | 227,337 | $18.38 | $4.18M | 4,939,489 |
| Apr 27, 2026 | Rhodes Jason P | director | Sell | 384,549 | $18.47 | $7.10M | 5,221,857 |
| Apr 23, 2026 | Kersten Dirk | director | Sell | 10,952 | $20.01 | $219.2K | 4,199,225 |
| Apr 22, 2026 | Rhodes Jason P | director | Sell | 834,302 | $19.75 | $16.48M0.5% OS | 5,554,904 |
| Apr 21, 2026 | Kersten Dirk | director | Sell | 337,248 | $20.21 | $6.82M | 4,332,799 |
| Apr 17, 2026 | Kersten Dirk | director | Sell | 99,613 | $20.35 | $2.03M | 4,562,546 |
| Apr 3, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 5,727 | $18.64 | $106.8K | 125,373 |
| Mar 13, 2026 | Kersten Dirk | director | Sell | 129,672 | $19.52 | $2.53M | 4,644,386 |
| Mar 11, 2026 | Kersten Dirk | director | Sell | 688,788 | $19.09 | $13.15M | 5,285,156 |
| Mar 6, 2026 | Cox John | director, officer: CEO & President | Sell | 2,732 | $14.90 | $40.7K | 374,145 |
| Mar 6, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 148 | $14.90 | $2.2K | 154,581 |
| Mar 6, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 904 | $14.90 | $13.5K | 171,606 |
| Dec 5, 2025 | Cox John | CEO & President | Sell | 2,662 | $20.72 | $55.2K | 196,877 |
| Dec 5, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 144 | $20.72 | $3.0K | 94,729 |
| Dec 5, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 880 | $20.72 | $18.2K | 87,510 |
| Sep 9, 2025 | Cox John | CEO & President | Sell | 2,640 | $13.41 | $35.4K | 199,539 |
| Sep 8, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 1,038 | $13.29 | $13.8K | 95,017 |
| Sep 8, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 4,425 | $13.30 | $58.8K | 89,263 |
| Jun 6, 2025 | Cox John | CEO & President | Sell | 4,060 | $13.35 | $54.2K | 142,179 |
DYN Insiders
Similar Stocks to DYN
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B